French Polynesia

Reimbursed Care Access

French Polynesia is an overseas collectivity of France with a legal regime that is largely governed by national French drug and health law except where texts expressly provide otherwise; as a result, the French classification of narcotics/psychotropes applies in practice and most classic psychedelic compounds are prohibited except where authorised under medical/regulated frameworks (notably esketamine as an authorised medicinal product in the EU/France). Medical anaesthetic use of ketamine is standard; other classical psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) remain controlled and unavailable for routine medical care outside tightly regulated research. [https://www.loc.gov/item/global-legal-monitor/2011-08-16/french-polynesia-new-law-on-the-functioning-of-governing-institutions/|Library of Congress: French Polynesia legal status] [https://www.has-sante.fr/jcms/p_3538219/fr/spravato-esketamine-depression|HAS: SPRAVATO advisory].